Heart Matters

Guest: Paul Sorajja, MD TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.